The first patient has been dosed in the pivotal Phase 3 KHENERFIN study evaluating sonlicromanol for the treatment of m.3243A>G primary mitochondrial disease. This milestone marks an important step in Khondrion’s lead program as it advances into the registrational phase of development. Khondrion is a clinical-stage biopharmaceutical company dedicated to developing therapies for patients with primary continue reading…